Integrative Hormone Care and Personalized Therapy

Integrative Hormone Care, Receptor Physiology, and Evidence-Based Delivery Systems for all individuals’ health

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through how hormones signal through receptors, why the selection of molecules and the route of administration affect outcomes, and how personalized, bioidentical hormone therapy supports cardiovascular, metabolic, bone, brain, and sexual health. I examine the Women’s Health Initiative (WHI) to explain how oral conjugated equine estrogens combined with a synthetic progestin are different from transdermal 17β-estradiol and micronized progesterone, and I provide a summary of current research on testosterone in men, including its safety. Throughout, I explain the physiological underpinnings—from endothelial nitric oxide signaling to GABAergic modulation—and show how integrative chiropractic care aligns autonomic balance, biomechanics, and movement to amplify endocrine benefits.

Why Molecule and Route Matter in Modern Hormone Care

When patients ask me why prior hormone therapies failed or caused side effects, I start with physiology. The molecule and route of delivery determine what signals reach tissues and how the liver, vasculature, and brain respond.

• Key insight from WHI: The landmark trials tested oral conjugated equine estrogens (CEE) combined with medroxyprogesterone acetate (MPA), a synthetic progestin. Those choices increased hepatic stimulation of clotting factors and altered lipid and inflammatory signaling, shifting risk unfavorably for venous thromboembolism (VTE) and some cardiometabolic endpoints (Manson et al., 2013).
• Modern practice: Using transdermal 17β-estradiol bypasses first-pass hepatic metabolism, reducing prothrombotic changes while preserving endothelial benefits, and pairing estradiol with oral micronized progesterone protects the endometrium with favorable effects on sleep and mood (The North American Menopause Society [NAMS], 2022; Vinogradova et al., 2019; L’Hermite, 2017).

Why this helps:

• Transdermal estradiol maintains physiologic signaling through ERα/ERβ, enhances endothelial nitric oxide synthase (eNOS) activity, and avoids the hepatic surge in coagulation proteins seen with oral routes (Canonico et al., 2016; Scarabin, 2018).
• Micronized progesterone binds native PR-A/PR-B receptors, delivers neuroactive metabolites (e.g., allopregnanolone) that improve GABAergic tone, and reliably protects the endometrium—effects many progestins do not replicate due to off-target androgenic and glucocorticoid actions (Stanczyk et al., 2013; Stute et al., 2016).

Clinically, switching symptomatic women from oral CEE to transdermal estradiol and adding nighttime micronized progesterone often calms hot flashes, stabilizes blood pressure variability, and improves sleep within weeks. (NAMS, 2022; L’Hermite, 2017).

Hormone Receptors: The Body’s Built-In Signaling Logic

Hormones are keys; receptors are the locks. When ligands bind receptors, cells initiate gene programs that govern vasodilation, mitochondrial output, bone remodeling, and neuroprotection (Hall et al., 2021).

• Estradiol (E2): High fidelity for ERα/ERβ drives eNOS activation, synaptic plasticity, lipid modulation, and osteoblast support (Taylor et al., 2019; Duarte-Guterman et al., 2015).
• Progesterone (P4): Via PR-A/PR-B, stabilizes endometrium, reduces neuroinflammation, and strengthens sleep architecture through GABA-A modulation (Bronson et al., 2022; Friess et al., 1997).
• Testosterone and DHT: Through androgen receptors, enhance mitochondrial biogenesis, protein synthesis, bone formation, erythropoiesis, libido, and drive; testosterone also aromatizes to estradiol in the brain, bone, and adipose (Kelly & Jones, 2013; Finkelstein et al., 2013).
• Thyroid hormones: Ubiquitous TR signaling orchestrates metabolic rate and mitochondrial respiration in nearly every cell (Mullur et al., 2014).

Clinical implication:

• Empty receptors mean under-stimulation. Declines in estradiol, progesterone, testosterone, or T3 manifest as fatigue, pain, dysautonomia, osteopenia, and cognitive drift. Restoring physiologic occupancy with bioidentical molecules aligns care with what cells are designed to receive (NAMS, 2022; L’Hermite, 2017).

Estradiol and Progesterone: Synergy Across the Lifespan

Estradiol and progesterone are synergists, not adversaries.

• Estradiol initiates growth and vascular readiness in the endometrium and brain, supports glucose transport and mitochondrial efficiency, and improves vascular compliance (Taylor et al., 2019).
• Progesterone orchestrates maturation and stabilization—reducing endometrial mitosis, calming neuroexcitable circuits via GABA-A modulation, and tempering glial activation (Bronson et al., 2022).

Why pair them:

• In women with a uterus, estradiol requires adequate progesterone to prevent endometrial hyperplasia. Oral micronized progesterone provides reliable tissue levels and sleep benefits; transdermal progesterone cream typically fails to achieve endometrial protection (Stute et al., 2016; NAMS, 2022).

Clinical observations:

• Nightly micronized progesterone improves sleep latency, reduces nocturnal awakenings, and often normalizes heart rate variability, especially when integrated with autonomic-balancing chiropractic care and breathing strategies (NAMS, 2022; Laborde et al., 2017).

Progestins vs Progesterone: A Crucial Distinction

Patients often ask, “Isn’t a progestin just progesterone?” No.

• Progesterone (bioidentical): Native receptor binding, neuroactive metabolites, better mood/sleep profile, and clean endometrial protection.
• Progestins (synthetic): Differing structures produce off-target effects—some are androgenic or glucocorticoid-like—altering lipids, insulin sensitivity, and breast tissue signaling (Stanczyk et al., 2013).

Evidence favors pairing transdermal estradiol with oral micronized progesterone when a uterus is present, prioritizing receptor fidelity and systemic harmony (L’Hermite, 2017; NAMS, 2022).

Testosterone Optimization: Men’s Health, Prostate Safety, and Cognitive Resilience

Calling testosterone a “male hormone” misses biology. Women utilize androgens throughout life, and men steadily lose testosterone from the third decade.

• Benefits: Properly dosed testosterone improves mood, sexual function, lean mass, and vitality in hypogonadal men (Bhasin et al., 2018; Snyder et al., 2016; Corona et al., 2014).
• Prostate safety: The androgen receptor saturation model shows that prostate ARs saturate at relatively low serum T levels; raising levels within physiologic ranges does not linearly increase intraprostatic signaling. Contemporary series in selected men show no increased recurrence after localized cancer treatment with careful monitoring (Morgentaler & Traish, 2009; Kaplan et al., 2019; Pastuszak et al., 2013).
• Cardiovascular outcomes: Meta-analyses and the TRAVERSE trial indicate no increase in major adverse cardiovascular events with physiologic therapy when monitored, while body composition and insulin sensitivity often improve (Hudson et al., 2022; Bhatt et al., 2023; Bhasin et al., 2018).
• Cognitive resilience: Low testosterone is associated with an increased risk of dementia; optimizing testosterone within physiologic ranges, integrated with sleep and resistance training, supports brain health (Pye et al., 2014; Cherrier et al., 2015).

Clinical reasoning:

• I confirm deficiency with two morning total T tests, evaluate free T with SHBG, and screen for secondary causes (sleep apnea and medications) before treatment. I monitor hematocrit, PSA, estradiol, and symptoms; I avoid supraphysiologic dosing and overuse of DHT blockade, which can worsen sexual function and mood in borderline-low T men (Traish, 2020; Bhasin et al., 2018).

Testosterone in Women: Energy, Libido, and Musculoskeletal Health

In women, low free testosterone with high SHBG frequently presents as low energy, reduced libido, and musculoskeletal pain—especially in midlife. Carefully titrated, low-dose transdermal or sublingual testosterone within physiologic female ranges can improve these domains, monitored for androgenic side effects (Islam et al., 2019; Davis & Wahlin-Jacobsen, 2015).

Clinical observation:

• When we reduce SHBG drivers and restore small, steady androgen signals, patients often report improved joint pain, strength, and daytime vitality, especially when paired with progressive resistance training and chiropractic-guided movement re-education.

Thyroid Signaling: The Metabolic Conductor

I regularly identify patients with normal TSH/T4 who still experience relative T3 deficit at tissues—cold intolerance, slowed cognition, dyslipidemia, and fatigue. Adjusting micronutrient levels (iodine, selenium, and iron) and, when indicated, treating thyroid dysfunction help restore mitochondrial performance and endocrine synergy (Mullur et al., 2014; Bianco & Dumitrescu, 2023).

Integrative Chiropractic Care: Autonomics, Biomechanics, and Endocrine Synergy

Hormone optimization is powerful—but context matters. My integrative chiropractic approach targets autonomic balance, spinal biomechanics, and movement capacity so hormones translate into daily performance.

• Autonomic regulation: Gentle joint mobilization, targeted manipulation, and breathwork reduce sympathetic overdrive and enhance vagal tone, improving sleep and reducing palpitations (Laborde et al., 2017).
• Biomechanics and vascular mechanics: Thoracic mobility increases rib cage excursion and diaphragmatic function, supporting venous return and reducing thoracic outlet strain that contributes to paresthesias in perimenopause.
• Muscle as an endocrine organ: Progressive resistance training activates mTOR, increases myokines, and improves insulin sensitivity—synergizing with testosterone and estradiol to rebuild lean mass and bone (Phillips, 2014).

From my clinic patterns:

• Patients who combine bioidentical hormone therapy with structured manual care, graded loading, sleep protocols, and precision nutrition exhibit faster gains in strength and mood, lower pain scores, and better adherence to lifestyle changes than hormone therapy alone.

Practical Protocols: Stepwise, Physiology-First Care

I tailor interventions to biology and goals, relying on symptom feedback and safety monitoring.

• For vasomotor symptoms, insomnia, and mood in women
  • Prefer transdermal 17β-estradiol for safer hepatic and thrombotic profiles; titrate to symptom control.
  • Use oral micronized progesterone at night for endometrial protection and sleep benefits if the uterus is present (NAMS, 2022; Stute et al., 2016).
  • Integrate cervical/thoracic mobility, diaphragmatic breathing, and resistance training.
• For men with hypogonadism
  • Confirm biochemical deficiency; address sleep apnea, medications, and metabolic drivers.
  • Start physiologic testosterone via gel, injection, or another route; target the upper quartile of young-adult free T if symptomatic, with hematocrit/PSA monitoring (Bhasin et al., 2018; Hudson et al., 2022).
  • Avoid routine DHT blockade; prioritize lifestyle to control aromatase.
• For women with low androgen symptoms
  • Evaluate total/free T and SHBG; consider microdose transdermal/sublingual testosterone within female reference ranges; monitor for acne or hirsutism (Islam et al., 2019).
  • Pair with progressive resistance training and protein optimization.
• Thyroid optimization
  • Correct micronutrient gaps; consider therapy when phenotype and labs align; support with autonomic balancing and mitochondrial-friendly training (Mullur et al., 2014; Bianco & Dumitrescu, 2023).

Follow-up and metrics:

• Track symptom scales (hot flashes, sleep, mood, and sexual function), vitals, lipids, A1c, and body composition; include HRV, pain scores, and functional tests. Adjust dosing and delivery to maintain physiologic range and ensure benefits map to outcomes.

Why These Strategies Work: Physiological Underpinnings

• Endothelial nitric oxide: Estradiol and testosterone upregulate eNOS, improving vasodilation and vascular compliance; transdermal estradiol avoids hepatic prothrombotic changes (Yanes et al., 2014; Vinogradova et al., 2019).
• GABAergic modulation: Micronized progesterone increases allopregnanolone, enhancing GABA-A activity for anxiolysis and sleep stability (Friess et al., 1997).
• Mitochondrial biogenesis and muscle protein synthesis: Testosterone activates PGC-1α and mTOR, restoring ATP output and strength; estradiol supports neuronal energy handling (Kelly & Jones, 2013; Finkelstein et al., 2013).
• Bone remodeling: Estradiol reduces RANKL signaling; testosterone stimulates periosteal formation—both supporting healthier turnover and density when combined with loading (Khosla & Monroe, 2018).

The clinical logic is straightforward: place the right molecules on the right receptors through the safest route, then create an external environment—sleep, movement, autonomic balance—where those signals can express as resilience, not just normalized labs.

Key Takeaways

• Use the right molecule and route: Transdermal 17β-estradiol plus oral micronized progesterone is often the safest and most physiological pair for many women (NAMS, 2022).
• Distinguish progesterone from progestins: Receptor fidelity and downstream effects differ; do not generalize progestin data to progesterone (Stanczyk et al., 2013).
• Optimize testosterone thoughtfully: In men, physiologic therapy can safely improve mood, sex, and energy with monitored prostate and cardiovascular parameters; in women, microdosed therapy can restore vitality when SHBG is high and free T is low (Bhasin et al., 2018; Islam et al., 2019).
• Integrate chiropractic care: Align the autonomic nervous system, biomechanics, and movement to translate endocrine signals into daily performance.
• Personalize and monitor: Track symptoms and function, not just numbers; adjust dose and delivery to minimize risk and maximize benefit.

References

• Bhasin, S., et al. (2018). Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.
• Bhatt, D. L., et al. (2023). Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). New England Journal of Medicine.
• Bianco, A. C., & Dumitrescu, A. M. (2023). Thyroid hormone economy and action in health and disease. Endocrine Reviews.
• Bronson, A., et al. (2022). Progesterone neuroprotection: Mechanisms of action and clinical implications. Neuroscience Letters.
• Canonico, M., Oger, E., & Plu-Bureau, G. (2016). Hormone therapy and venous thromboembolism among postmenopausal women: Updated evidence. Thrombosis Research.
• Cherrier, M. M., et al. (2015). Testosterone and cognitive function: Systematic review and recommendations. Alzheimer’s & Dementia.
• Corona, G., et al. (2014). Testosterone and depression: A systematic review and meta-analysis. Andrology.
• Duarte-Guterman, P., et al. (2015). Complex interactions between sex hormones and the brain. Frontiers in Neuroendocrinology.
• Finkelstein, J. S., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine.
• Friess, E., et al. (1997). Progesterone-induced changes in sleep. American Journal of Physiology.
• Hall, J. M., et al. (2021). Steroid hormone receptors in health and disease. Nature Reviews Endocrinology.
• Hudson, J., et al. (2022). Testosterone therapy and cardiovascular risk: Meta-analysis of randomized trials. JAMA Internal Medicine.
• Islam, R. M., et al. (2019). Safety and efficacy of testosterone for women: A systematic review and meta-analysis. The Lancet Diabetes & Endocrinology.
• Kaplan, A. L., et al. (2019). Testosterone therapy in men with treated and untreated prostate cancer. Urology.
• Kelly, D. M., & Jones, T. H. (2013). Testosterone: A metabolic hormone in health and disease. Journal of Endocrinology.
• Khosla, S., & Monroe, D. G. (2018). Sex steroids, bone remodeling, and osteoporosis prevention. Nature Reviews Endocrinology.
• Laborde, S., et al. (2017). Heart rate variability and cardiac vagal tone in psychophysiology. International Journal of Psychophysiology.
• L’Hermite, M. (2017). Bioidentical menopausal hormone therapy: Registered hormones (estradiol, progesterone) are optimal. Climacteric.
• Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes during WHI. New England Journal of Medicine.
• Morgentaler, A., & Traish, A. (2009). The saturation model and prostate cancer. Journal of Sexual Medicine.
• Mullur, R., et al. (2014). Thyroid hormone regulation of metabolism. Physiological Reviews.
• NAMS. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause.
• Pastuszak, A. W., et al. (2013). Testosterone therapy after prostate cancer treatment. International Journal of Impotence Research.
• Phillips, S. M. (2014). Resistance training and muscle protein turnover. Physiological Reviews.
• Pye, S. R., et al. (2014). Relationship between testosterone and cognitive function in aging men. Journal of Clinical Endocrinology & Metabolism.
• Scarabin, P. Y. (2018). Progestogens and venous thromboembolism in menopausal women. Climacteric.
• Snyder, P. J., et al. (2016). Effects of testosterone treatment on risk markers and function. Annals of Internal Medicine.
• Stanczyk, F. Z., et al. (2013). Progestogens used in contraception and hormone therapy. Endocrine Reviews.
• Stute, P., et al. (2016). Impact of micronized progesterone on the endometrium: Systematic review. Climacteric.
• Taylor, M., Keevil, B., & Huhtaniemi, I. (2019). Estradiol and cognitive function. Frontiers in Neuroendocrinology.
• Vinogradova, Y., et al. (2019). HRT and risk of venous thromboembolism. BMJ.
• Yanes, L. L., et al. (2014). Effects of testosterone on arterial stiffness and endothelial function. Hypertension.